Skip to main content

Table 7 Comparison between patients who developed pazopanib-related cardiovascular toxicity after excluding hypertension

From: Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

Patient Characteristics Pazopanib-induced non-HTN CV toxicity (N = 12) No Pazopanib-induced non-HTN CV toxicity (N = 23) P Value
Male Gender 5 (42) 15 (65) 0.282
Age, years 66 [61-71] 57 [52-65] 0.006
LVEF, % *60 [59-67] **62.5 [59-66] 0.712
Systolic BP, mm Hg 124.1 [120.8-130.8] 127.7 [122-132.6] 0.728
Diastolic BP, mm Hg 70.0 [65.9-73.5] 72 [67.9-79.3] 0.297
Heart Failure 0 (0) 2 (9) 0.536
LV Dysfunction 4 (33) 3 (13) 0.200
Diabetes Mellitus 5 (42) 10 (43) 1
Hypertension 7 (58) 14 (61) 1
Dyslipidemia 8 (67) 9 (39) 0.164
GFR < 60 mL/min/1.73 m2 9 (75) 11 (48) 0.163
CAD/PAD 3 (25) 2 (9) 0.313
CVA/TIA 3 (25) 0 (0) 0.034
Dysrhythmia 3 (25) 4 (17) 0.670
Thromboembolism 1 (8) 6 (26) 0.380
Smoker*, n (%) 7 (58) 13 (57) 1
BMI (kg/m2) 27.6 [23.6-31.8] 28.5 [21.9-32.9] 0.627
ACEIs or ARBs 6 (50) 8 (35) 0.383
Beta Blockers 4 (33) 8 (35) 1
Statin 6 (50) 7 (30) 0.256
Pazopanib dose reduction 3 (25) 3 (13) 0.391
Follow-up time, months 11.7 [4.2-20.9] 6.9 [2.1-17.7] 0.509
  1. ACEI angiotensin converting enzyme, ARB angiotensin receptor blocker, BP blood pressure, BMI body mass index, CAD/PAD coronary artery disease/peripheral arterial disease, CCBs calcium channel blockers, ECOG Eastern Cooperative Oncology Group performance status, LVEF left ventricular ejection fraction, GRF glomerular filtration rate; Data presented as a percent (%) or median [1st quartile-3rd quartile]
  2. * N = 9; ** N = 16
  3. aCurrent or prior smoking history